Pentwater Capital Management LP Autolus Therapeutics PLC Transaction History

Pentwater Capital Management LP

  • $9.58 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$1.74 - $3.27 $696,000 - $1.31 Million
400,000 New
400,000 $760,000
Q4 2018

Feb 14, 2019
SELL
$24.21 - $48.01 $323,203 - $640,933
-13,350 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$20.86 - $33.33 $34,419 - $54,994
-1,650 Reduced 11.0%
13,350 $409,000
Q2 2018

Aug 14, 2018
BUY
$25.0 - $27.75 $375,000 - $416,250
15,000 New
15,000 $402,000

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $205M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Pentwater Capital Management LP Portfolio

Follow Pentwater Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Pentwater Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email